Head of Clinical Site Development & Expansion appointed to lead TrialsWest east-coast network
Resonance Health (ASX: RHT) has appointed an experienced clinical operations leader as Head of Clinical Site Development & Expansion, leading the east-coast expansion of its TrialsWest clinical trial site network. The appointment formally commences on 1 December 2026.
The role is funded by the recent Placement. It was referenced as “East-Coast General Manager” in the Placement investor presentation released to the ASX on 27 October 2026.
The recent Placement also earmarked capital for the liver fibrosis MRI device, which management is advancing toward FDA Pre-Submission feedback alongside the clinical site build-out.
Key facts on the appointment:
- More than 25 years’ experience across investigator sites, research governance, global pharma and biotech
- Based on the east coast
- A registered nurse by background
- Site identification has commenced in the Company’s targeted east-coast regions
With the appointment in place, the east-coast expansion has a dedicated leader as site identification progresses.
Andrew Harrison, CEO & Managing Director
“…Site identification is underway, and from 1 December 2026 the job is execution.”
When big ASX news breaks, our subscribers know first
Inside the executive’s 25-year clinical trial track record
The executive’s background spans several parts of the clinical trial ecosystem:
- Most recently, employed by a clinical-stage biotechnology company, where they were accountable for clinical research activities across Phase I-III studies.
- Before that, at a global pharmaceutical company, where they built the Australian study start-up capability, led site intelligence and investigator engagement for global study placement, and accelerated protocol receipt to the clinical trial’s first-subject-visit.
- Earlier, research governance across public and private health networks, and contributing to state health policy reforms that streamlined ethical review of multicentre research.
Mr Harrison said the executive has spent more than 25 years on every side of a clinical trial and has learned “exactly what sponsors look for when they place a study.” That sponsor-side experience bears directly on how new sites win study placements.
How the nine-site national network model works
The east-coast strategy largely replicates TrialsWest’s west-coast site model. Resonance Health and TrialsWest aim to build a nine-site national network: the three existing Western Australian sites (Spearwood, Osborne Park and Mandurah) plus six new east-coast sites, run in a “hub-and-spoke” model from TrialsWest’s headquarters.
A clinical trial site is a location where studies of new treatments are run with participants. Pharmaceutical companies and contract research organisations (CROs), which manage trials on behalf of sponsors, place studies at sites they trust. A model already proven in one region may lower the rollout risk of repeating it elsewhere.
The company points to its WA results as proof of the model:
| Metric | Figure | Context |
|---|---|---|
| TrialsWest FY26 revenue (three WA sites) | $4.1 million | Revenue before intercompany eliminations |
| Osborne Park | $2 million | Annualised run-rate in only its third year |
| Mandurah | n/a | Close to achieving breakeven in its first year |
| Active trials | 20+ | Existing TrialsWest active trials |
Per-site requirements are modest:
- About $100,000 of fit-out capex per new site
- Two FTE per site, including a Principal Investigator who will be engaged before each site is committed
Mr Harrison said TrialsWest has built its WA business on strong pharma and CRO relationships. “The east-coast network will receive workflow from these sponsors and the studies we already run for them, not from a standing start,” he said.
Together, a model proven in WA, low fit-out capex per site and existing sponsor relationships frame the rollout as a capital-light growth path.
What happens next for TrialsWest’s east-coast rollout
The announcement sets out the following timing:
- 1 December 2026: the appointment of the Head of Clinical Site Development & Expansion formally commences.
- Site identification: has already commenced in the Company’s targeted east-coast regions.
- First east-coast sites: expected to open from the second half of FY27 (January to June 2027), at a rate of approximately two a year.
New clinical trial sites are excluded from the Company’s FY27 guidance.
For readers wanting the group-level picture behind these site figures, our detailed coverage of the FY26 full year results sets out how the three business segments each turned a profit and what FY27 guidance assumes.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors getting FREE breaking ASX news delivered to their inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive healthcare alerts the moment market-moving announcements break and stay ahead of the market.